Gennova Biopharmaceuticals Working On Omicron-Specific Covid Vaccine Using mRNA Tech

India's Gennova Biopharmaceuticals is working on an Omicron-specific COVID-19 vaccine candidate that could be ready in a month or two.

The source, who did not want to be named as the information was private, said the product might need a small trial in India before it could be rolled out as a booster or standalone vaccine.

A representative for Gennova, a unit of drugmaker Emcure Pharmaceuticals that does business in some 70 countries, did not immediately respond to a request for comment.

Leave a Reply